Phase 3 Development of First-in-Class C5a Inhibitor Vilobelimab: Transforming Treatment for Pyoderma Gangrenosum
Time: 3:15 pm
day: Day One
Details:
- Understand C5a inhibition how demonstrates a novel mechanism for targeting neutrophil-driven inflammation in PG
- Examine Phase 1 and 2a clinical data showcasing safety profile and biological proof of concept across multiple indications
- Discover the strategic approach to Phase 3 trial design that builds on demonstrated efficacy while addressing rare disease challenges
